SK286779B6 - N-Heterocyklické deriváty ako inhibítory NOS, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie - Google Patents
N-Heterocyklické deriváty ako inhibítory NOS, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie Download PDFInfo
- Publication number
- SK286779B6 SK286779B6 SK1135-99A SK113599A SK286779B6 SK 286779 B6 SK286779 B6 SK 286779B6 SK 113599 A SK113599 A SK 113599A SK 286779 B6 SK286779 B6 SK 286779B6
- Authority
- SK
- Slovakia
- Prior art keywords
- alkyl
- optionally substituted
- formula
- heterocyclyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80897597A | 1997-02-19 | 1997-02-19 | |
US2512498A | 1998-02-17 | 1998-02-17 | |
PCT/US1998/003176 WO1998037079A1 (en) | 1997-02-19 | 1998-02-19 | N-heterocyclic derivatives as nos inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
SK113599A3 SK113599A3 (en) | 2000-07-11 |
SK286779B6 true SK286779B6 (sk) | 2009-05-07 |
Family
ID=26699322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1135-99A SK286779B6 (sk) | 1997-02-19 | 1998-02-19 | N-Heterocyklické deriváty ako inhibítory NOS, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP1754703A3 (de) |
JP (1) | JP4495257B2 (de) |
KR (1) | KR20000075615A (de) |
CN (1) | CN1100777C (de) |
AT (1) | ATE345339T1 (de) |
AU (1) | AU732969B2 (de) |
CA (1) | CA2281545C (de) |
CZ (1) | CZ2008628A3 (de) |
DE (1) | DE69836422T2 (de) |
DK (1) | DK0968206T3 (de) |
ES (1) | ES2277382T3 (de) |
GB (1) | GB2338957B (de) |
HK (1) | HK1025952A1 (de) |
IL (1) | IL131475A0 (de) |
NO (1) | NO321664B1 (de) |
NZ (1) | NZ337861A (de) |
PL (1) | PL335235A1 (de) |
PT (1) | PT968206E (de) |
RU (1) | RU2241708C2 (de) |
SK (1) | SK286779B6 (de) |
WO (1) | WO1998037079A1 (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
AU725548B2 (en) * | 1997-03-11 | 2000-10-12 | E.I. Du Pont De Nemours And Company | Heteroaryl azole herbicides |
DE19836697A1 (de) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
US6432959B1 (en) * | 1998-12-23 | 2002-08-13 | Schering Corporation | Inhibitors of farnesyl-protein transferase |
IL142816A0 (en) | 1998-12-24 | 2002-03-10 | Du Pont Pharm Co | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
AUPQ142599A0 (en) * | 1999-07-05 | 1999-07-29 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
AU777735B2 (en) | 1999-07-15 | 2004-10-28 | Pharmacopeia, Inc. | Bradykinin B1 receptor antagonists |
US7037916B2 (en) * | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
EP1218377A1 (de) | 1999-10-08 | 2002-07-03 | Bristol-Myers Squibb Pharma Company | Amino-lactam-sulfonamide als inhibitoren der bildung von a-beta-amyloid-protein |
US6462046B2 (en) * | 2000-01-06 | 2002-10-08 | Advanced Syntech, Llc | Heterocycle derivatives as PPAR-gamma agonists |
DE10005570A1 (de) | 2000-02-09 | 2001-08-16 | Bayer Ag | Verfahren zur Herstellung von 2-Methoxyethoxy-benzolen und neue 2-Methoxyethoxy-benzylcyanide |
US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
GB2361473C (en) * | 2000-03-08 | 2005-06-28 | Microgenics Corp | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
CA2403550A1 (en) | 2000-04-03 | 2001-10-11 | Hong Liu | Cyclic lactams as inhibitors of a-.beta. protein production |
BR0107532A (pt) | 2000-04-03 | 2004-11-03 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica |
US6632812B2 (en) | 2000-04-11 | 2003-10-14 | Dupont Pharmaceuticals Company | Substituted lactams as inhibitors of Aβ protein production |
BR0106717A (pt) | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
DE60134679D1 (de) * | 2000-10-20 | 2008-08-14 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische Heterozyklen |
US20030055249A1 (en) * | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
JPWO2003026661A1 (ja) * | 2001-09-14 | 2005-01-06 | 山之内製薬株式会社 | インスリン分泌促進剤及び新規なピリミジン誘導体 |
US20060100196A1 (en) * | 2001-09-24 | 2006-05-11 | Andrea Gailunas | Substituted amines for the treatment of alzheimer's disease |
EP1795192A3 (de) * | 2002-04-30 | 2008-05-07 | Bayer Schering Pharma Aktiengesellschaft | 1-(pyridazin-3-yl)-Imidazol Derivaten als NO-Synthase (NOS) Hemmer |
US6982259B2 (en) * | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
CN1674885A (zh) * | 2002-08-02 | 2005-09-28 | 法玛西雅公司 | 治疗和预防胃肠病症的方法 |
AU2003260033A1 (en) * | 2002-08-29 | 2004-03-19 | Schering Aktiengesellschaft | Methods of treating acute respiratory distress syndrome |
US7759336B2 (en) * | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
MXPA06002608A (es) | 2002-12-20 | 2007-01-23 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
WO2004069829A1 (en) * | 2003-01-10 | 2004-08-19 | Pharmacopeia Drug Discovery, Inc. | (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis |
EP1601665A2 (de) * | 2003-03-07 | 2005-12-07 | Glaxo Group Limited | Harnstoff-derivate und deren verwendung als vanilloidrezeptorantagonisten zur behandlung von schmerzen |
EP1683785B1 (de) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Harnstoffderivate und verfahren zu deren herstellung |
JP4503022B2 (ja) | 2003-12-23 | 2010-07-14 | ファイザー・インク | 新規キノリン誘導体 |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
DK1718608T3 (da) | 2004-02-20 | 2013-10-14 | Boehringer Ingelheim Int | Virale polymeraseinhibitorer |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
CA2564199A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
EP1756090A1 (de) | 2004-05-14 | 2007-02-28 | Pfizer Products Incorporated | Pyrimidinderivate zur behandlung von anormalem zellwachstum |
EP1751142A1 (de) | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Pyrimidinderivate zur behandlung von anormalem zellwachstum |
ES2322175T3 (es) | 2004-09-17 | 2009-06-17 | EISAI R&D MANAGEMENT CO., LTD. | Composicion medicinal con estabilidad mejorada y gelificacion reducida. |
EP1791830B1 (de) * | 2004-09-17 | 2010-12-29 | Vertex Pharmaceuticals Incorporated | Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen |
US7652009B2 (en) | 2004-11-30 | 2010-01-26 | Amgem Inc. | Substituted heterocycles and methods of use |
BRPI0518096A (pt) * | 2004-12-01 | 2008-10-28 | Kalypsys Inc | composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
EP2586445A1 (de) * | 2005-04-15 | 2013-05-01 | University Of North Carolina At Chapel Hill | Verfahren zur Ermöglichung des Überlebens von Nervenzellen mit Neurotrophin-Mimetika |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
JPWO2007020888A1 (ja) | 2005-08-12 | 2009-02-26 | 武田薬品工業株式会社 | 脳・神経細胞保護剤および睡眠障害治療薬 |
WO2007039581A1 (en) * | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted diazabenzophenone compounds |
CN101454317A (zh) * | 2005-11-28 | 2009-06-10 | 凯利普西斯公司 | 作为一氧化氮合酶二聚化抑制剂的咪唑衍生物 |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
MX2009000310A (es) * | 2006-07-14 | 2009-01-26 | Novartis Ag | Derivados de pirimidina como inhibidores de alk-5. |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
WO2008042925A1 (en) * | 2006-10-04 | 2008-04-10 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
EP1939181A1 (de) * | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression |
KR101445892B1 (ko) | 2007-01-29 | 2014-09-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암 치료용 조성물 |
US8952035B2 (en) | 2007-11-09 | 2015-02-10 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
EP2331095B1 (de) * | 2008-08-04 | 2014-10-15 | CHDI Foundation, Inc. | Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür |
AU2010319349B2 (en) | 2009-11-12 | 2015-07-16 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
BR112012032462A2 (pt) | 2010-06-25 | 2016-11-08 | Eisai R&D Man Co Ltd | agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase. |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
EP3444363B1 (de) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen |
PL2750677T3 (pl) | 2011-08-30 | 2017-12-29 | Chdi Foundation, Inc. | Inhibitory 3-monooksygenazy kinureninowej, kompozycje farmaceutyczne i sposoby ich stosowania |
WO2013052395A1 (en) * | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine pde10 inhibitors |
WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
RS58374B1 (sr) | 2013-03-12 | 2019-03-29 | Vertex Pharma | Inhibitori dnk-pk |
ES2687968T3 (es) | 2013-05-14 | 2018-10-30 | Eisai R&D Management Co., Ltd. | Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib |
EP3057953B1 (de) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-kristalle von (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)chinolin-4-carboxamid und deuterierten derivaten davon als dna-pk-hemmer |
BR112017000922A2 (pt) | 2014-07-17 | 2018-01-16 | Chdi Foundation, Inc. | métodos e composições para tratar distúrbios relacionados ao hiv |
BR112017002827B1 (pt) | 2014-08-28 | 2023-04-18 | Eisai R&D Management Co., Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
MX2017010474A (es) | 2015-02-25 | 2017-11-28 | Eisai R&D Man Co Ltd | Metodo para suprimir el amargor de un derivado de quinoleina. |
KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
US20200377481A1 (en) * | 2016-06-07 | 2020-12-03 | Northwestern University | Substituted 4-(1-pyrrolidinyl)pyrimidine compounds as dimerization inhibitors of neuronal nitric oxide synthase |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
RU2732297C2 (ru) * | 2018-11-14 | 2020-09-15 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Производные нестероидных противовоспалительных средств |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6339875A (ja) * | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
DK0640599T3 (da) * | 1993-08-26 | 1998-09-28 | Ono Pharmaceutical Co | 4-Aminopyrimidin-derivater |
-
1998
- 1998-02-19 AU AU61749/98A patent/AU732969B2/en not_active Ceased
- 1998-02-19 PL PL98335235A patent/PL335235A1/xx not_active Application Discontinuation
- 1998-02-19 RU RU99120077/04A patent/RU2241708C2/ru active
- 1998-02-19 WO PCT/US1998/003176 patent/WO1998037079A1/en active Application Filing
- 1998-02-19 JP JP53685398A patent/JP4495257B2/ja not_active Expired - Fee Related
- 1998-02-19 SK SK1135-99A patent/SK286779B6/sk not_active IP Right Cessation
- 1998-02-19 IL IL13147598A patent/IL131475A0/xx not_active IP Right Cessation
- 1998-02-19 CA CA002281545A patent/CA2281545C/en not_active Expired - Fee Related
- 1998-02-19 ES ES98906555T patent/ES2277382T3/es not_active Expired - Lifetime
- 1998-02-19 GB GB9919686A patent/GB2338957B/en not_active Expired - Fee Related
- 1998-02-19 CZ CZ2008-628A patent/CZ2008628A3/cs unknown
- 1998-02-19 KR KR1019997007678A patent/KR20000075615A/ko not_active Application Discontinuation
- 1998-02-19 PT PT98906555T patent/PT968206E/pt unknown
- 1998-02-19 AT AT98906555T patent/ATE345339T1/de not_active IP Right Cessation
- 1998-02-19 DK DK98906555T patent/DK0968206T3/da active
- 1998-02-19 EP EP06023449A patent/EP1754703A3/de not_active Withdrawn
- 1998-02-19 NZ NZ337861A patent/NZ337861A/xx unknown
- 1998-02-19 DE DE69836422T patent/DE69836422T2/de not_active Expired - Lifetime
- 1998-02-19 CN CN98804281A patent/CN1100777C/zh not_active Expired - Fee Related
- 1998-02-19 EP EP98906555A patent/EP0968206B8/de not_active Expired - Lifetime
-
1999
- 1999-08-19 NO NO19993996A patent/NO321664B1/no not_active IP Right Cessation
-
2000
- 2000-07-11 HK HK00104236A patent/HK1025952A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK286779B6 (sk) | N-Heterocyklické deriváty ako inhibítory NOS, spôsob ich prípravy, farmaceutické prostriedky s ich obsahom a ich použitie | |
US6432947B1 (en) | N-heterocyclic derivatives as NOS inhibitors | |
CZ303169B6 (cs) | Heterocyklické benzensulfonamidové slouceniny jako antagonisty bradykininu | |
MXPA99007670A (en) | N | |
CZ296799A3 (cs) | N-Heterocyklické deriváty jako inhibitory NOS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20100219 |